Cargando…
The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373002/ https://www.ncbi.nlm.nih.gov/pubmed/35621725 http://dx.doi.org/10.18553/jmcp.2022.28.6.680 |
| _version_ | 1785078472139341824 |
|---|---|
| author | Nikitin, Dmitriy Lin, Grace A Campbell, Jon D Hansen, Ryan N Brouwer, Elizabeth Chen, Yilin Herron-Smith, Serina Agboola, Foluso Pearson, Steven D |
| author_facet | Nikitin, Dmitriy Lin, Grace A Campbell, Jon D Hansen, Ryan N Brouwer, Elizabeth Chen, Yilin Herron-Smith, Serina Agboola, Foluso Pearson, Steven D |
| author_sort | Nikitin, Dmitriy |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10373002 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103730022023-07-31 The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council Nikitin, Dmitriy Lin, Grace A Campbell, Jon D Hansen, Ryan N Brouwer, Elizabeth Chen, Yilin Herron-Smith, Serina Agboola, Foluso Pearson, Steven D J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2022-06 /pmc/articles/PMC10373002/ /pubmed/35621725 http://dx.doi.org/10.18553/jmcp.2022.28.6.680 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Perspectives on Value Nikitin, Dmitriy Lin, Grace A Campbell, Jon D Hansen, Ryan N Brouwer, Elizabeth Chen, Yilin Herron-Smith, Serina Agboola, Foluso Pearson, Steven D The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title | The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_full | The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_fullStr | The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_full_unstemmed | The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_short | The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council |
| title_sort | effectiveness and value of tirzepatide for type 2 diabetes mellitus: a summary from the institute for clinical and economic review’s new england comparative effectiveness public advisory council |
| topic | Perspectives on Value |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373002/ https://www.ncbi.nlm.nih.gov/pubmed/35621725 http://dx.doi.org/10.18553/jmcp.2022.28.6.680 |
| work_keys_str_mv | AT nikitindmitriy theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT lingracea theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT campbelljond theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT hansenryann theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT brouwerelizabeth theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT chenyilin theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT herronsmithserina theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT agboolafoluso theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend theeffectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT nikitindmitriy effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT lingracea effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT campbelljond effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT hansenryann effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT brouwerelizabeth effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT chenyilin effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT herronsmithserina effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT agboolafoluso effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend effectivenessandvalueoftirzepatidefortype2diabetesmellitusasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil |